In addition to its anti-FLT3 activity, sorafenib has been shown to induce interleukin-15 production by FLT3-positive leukemia cells, thereby activating the donor CD8+ T cells and promoting the GVL effect (48). The gene discussed is FLT3; the disease is leukemia.